Pulmonx (LUNG) Projected to Post Quarterly Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) is expected to be issuing its quarterly earnings data after the market closes on Wednesday, February 19th. Analysts expect the company to announce earnings of ($0.45) per share and revenue of $22.29 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Pulmonx Stock Performance

Shares of NASDAQ:LUNG opened at $6.97 on Tuesday. The company has a market capitalization of $275.25 million, a price-to-earnings ratio of -4.74 and a beta of 0.64. Pulmonx has a 52 week low of $5.46 and a 52 week high of $14.84. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. The firm has a 50 day moving average of $6.41 and a 200 day moving average of $6.74.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on LUNG shares. Wells Fargo & Company reduced their price target on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 11th. Citigroup reaffirmed a “neutral” rating and set a $7.50 price target (down from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Finally, Stifel Nicolaus reduced their price target on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $12.75.

Insider Activity at Pulmonx

In other Pulmonx news, General Counsel David Aaron Lehman sold 5,497 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $6.19, for a total value of $34,026.43. Following the sale, the general counsel now directly owns 197,851 shares of the company’s stock, valued at approximately $1,224,697.69. This represents a 2.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Glendon E. French III sold 20,000 shares of the stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $6.63, for a total value of $132,600.00. Following the sale, the director now directly owns 1,071,974 shares in the company, valued at $7,107,187.62. This represents a 1.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,199 shares of company stock valued at $208,859 in the last ninety days. Company insiders own 5.70% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.